SLC31A2 and ovarian carcinoma: Kristin et al. (Bompiani et al., 2016) knocked out the CTR1, CTR2, ATOX1, and CCS using CRISPR-Cas9 genome editing; and the results indicated that the loss of CTR1, CTR2, ATOX1, or CCS had little impact on cisplatin sensitivity in both human HEK-293T and ovarian carcinoma OVCAR8 cells.